The partnership puts Scality's software-defined S3 object storage layer, which already manages tiering across flash, disk and tape, alongside Biomemory's industrial-grade DNA storage systems. The integration will position DNA as a new cold archive tier within Scality's ADI (autonomous data infrastructure) solution, governed by its existing lifecycle and cyber-resilience policies.
The use cases targeted are the ones where longevity and immutability matter most: national and government archives, genomic and scientific data repositories, media and entertainment preservation, regulated healthcare and financial records, sovereign and defence workloads. DNA storage requires no media refreshes and draws no power while at rest — properties that tape can approximate but not match over multi-decade timescales.
Scality CEO Jerome Lecat is taking a seat on Biomemory's board, a structure that signals commercial intent rather than arms-length technology licensing. Biomemory also recently acquired assets from Catalog Technologies, the American DNA storage pioneer, adding engineering depth ahead of the integration work.
The integration roadmap is described as joint, with milestones to be published as the work progresses. Scality frames its role as the control plane — governing how data moves into and out of DNA storage, how policies are enforced, and how resilience is maintained across storage tiers.
Biomemory is based in Paris with R&D and production in Boston; Scality is headquartered in the US with a significant European customer base spanning enterprise, media and government sectors.
To stay across the latest in cloud, AI and enterprise tech analysis from Compare the Cloud, subscribe to our weekly newsletter at https://www.comparethecloud.net/newsletter
